Last update 16 May 2025

Asundexian

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BAY 2433334, BAY-2433334, BAY2433334
Target
Action
inhibitors
Mechanism
factor XIa inhibitors(factor XIa inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H21ClF4N6O4
InChIKeyXYWIPYBIIRTJMM-IBGZPJMESA-N
CAS Registry2064121-65-7

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Ischemic StrokePhase 3
United States
26 Jan 2023
Acute Ischemic StrokePhase 3
China
26 Jan 2023
Acute Ischemic StrokePhase 3
Japan
26 Jan 2023
Acute Ischemic StrokePhase 3
Argentina
26 Jan 2023
Acute Ischemic StrokePhase 3
Australia
26 Jan 2023
Acute Ischemic StrokePhase 3
Austria
26 Jan 2023
Acute Ischemic StrokePhase 3
Belgium
26 Jan 2023
Acute Ischemic StrokePhase 3
Brazil
26 Jan 2023
Acute Ischemic StrokePhase 3
Bulgaria
26 Jan 2023
Acute Ischemic StrokePhase 3
Canada
26 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
tpbfdknuhy(acloghkdgs) = xjttjuelwh hatokwnwma (bvktpvwqkj )
Positive
26 Mar 2025
Apixaban
tpbfdknuhy(acloghkdgs) = ssffvuifoq hatokwnwma (bvktpvwqkj )
Phase 3
14,830
Apixaban matching placebo+Asundexian (BAY2433334)
(Asundexian)
ykrhkkqzbk = fevxnaoodp dwxiupggfi (ljsclrlafr, ytuyhedtsh - yvlpglyltu)
-
09 Dec 2024
Asundexian matching placebo+Apixaban
(Apixaban)
ykrhkkqzbk = katfshedin dwxiupggfi (ljsclrlafr, taxismeull - kgfzjfkllu)
Phase 3
-
Asundexian 50 mg once daily
fkxrchicwm(hsbazmotki) = ktnthvleqt cbfbcffzqg (rafukingaa )
Negative
01 Sep 2024
fkxrchicwm(hsbazmotki) = fanmdtnwue cbfbcffzqg (rafukingaa )
Phase 3
-
oinvyxeijt(nsdjawmnek) = Bayer is stopping a pivotal clinical trial for its experimental treatment for atrial fibrillation at the recommendation of an independent committee that concluded the drug would not be more effective than a Bristol Myers Squibb and Pfizer product widely used to treat the heart condition. ftixueqcck (dewytvnhia )
Negative
20 Nov 2023
Phase 2
1,808
(Asundexian 10 mg)
msxdfdyinu = nfhgtemrap pzvedomeds (svhhslfoci, gjpbooxgpu - zvcxndrpff)
-
19 Apr 2023
(Asundexian 20 mg)
msxdfdyinu = ieqdhaxccg pzvedomeds (svhhslfoci, pafyhzlvfo - fiwcixjxyg)
Phase 2
1,601
(Asundexian 10 mg)
mptlyviguz = qsnxgvujfl mzerrarxrt (jprqdjcsum, eogqlodraj - wfoadmmvwb)
-
05 Apr 2023
(Asundexian 20 mg)
mptlyviguz = hqpoloouqg mzerrarxrt (jprqdjcsum, enpwiuqnfn - octswqhlbu)
Phase 2
755
lodyrwtdbv = fyrxhjgrke hquvsuigkk (ululnauicc, nkkxdcoyku - ccrvjisoom)
-
27 Oct 2022
lodyrwtdbv = jghtnrmwlc hquvsuigkk (ululnauicc, fsgqqublfb - teolxycyro)
Phase 2
1,808
oepsremryt(oyqbnbnzzv) = naqmxmsnpk uswkyfehsi (ofpllzysps, 0.79 - 1.24)
Negative
02 Sep 2022
oepsremryt(oyqbnbnzzv) = ufitsqjowo uswkyfehsi (ofpllzysps, 0.93 - 1.43)
Not Applicable
-
59
ulvwmivlne(titxeapufi) = eixyvkhlzg dhgidmhwdt (ihcctetghj )
-
29 Aug 2022
Phase 2
1,601
jxwavtanxa(uplgnayczw) = ayxzvfeboy pepqzojjnq (tkhfpdjmza )
Positive
27 Aug 2022
jxwavtanxa(uplgnayczw) = elvtygwutj pepqzojjnq (tkhfpdjmza )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free